TECVAYLI

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Italy, Lithuania.

Active ingredients

The drug TECVAYLI contains one active pharmaceutical ingredient (API):

1	Teclistamab UNII 54534MX6Z9 - TECLISTAMAB
	Teclistamab is a full-size, IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. With its dual binding sites, teclistamab is able to draw CD3+ T cells in close proximity to BCMA+ cells, resulting in T cell activation and subsequent lysis and death of BCMA+ cells, which is mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T cells.
	Read more about Teclistamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TECVAYLI Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX24		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3040636, 3040647
FR	Base de données publique des médicaments	61368383, 61935054
IT	Agenzia del Farmaco	050296019, 050296021
LT	Valstybinė vaistų kontrolės tarnyba	1095409, 1095410
US	FDA, National Drug Code	57894-449, 57894-450